Can aspirin reduce the risk of breast Ca?


Women who take aspirin regularly are about 26% less likely to develop breast cancer than those who don't, according to New York researchers.

The population-based case–control study of almost 3,000 women with and without breast cancer found the association to be strongest among women who take at least one tablet of aspirin per day, among those who take aspirin alone or with other nonsteroidal anti-inflammatory drugs (NSAIDS) (as opposed to other NSAIDS alone), and among current and recent users (within the last 5 years). And they specifically found that aspirin protected most against hormone receptor-positive cancers, reducing the risk by 26% (OR 0.74, 95% CI 0.60–0.93). The findings did not pertain to ibuprofen or acetaminophen.


How might COX-2 inhibitors like aspirin slow down estrogen biosynthesis? In the receptor-positive breast cancer cell at the top of the drawing (1),, various tumor promotors stimulate production of the enzyme cyclooxygenase 2 (COX-2) which in turn is responsible for prostaglandin synthesis (2). Increased PGE2 production then prompts the formation of aromatase (3) (4), the crucial enzyme that catalyzes the conversion of androgens to estrogens (5). The new research suggests that COX-2 inhibitors block prostaglandin synthesis, slowing down the long chain of events that leads to estrogen production in cancer cells.

While the mechanism of prevention is unclear, experts surmise that inhibition of estrogen biosynthesis plays an important role, as the illustration to the right suggests. While experts generally agree that it is too soon for all women to begin taking aspirin daily solely to prevent breast cancer, clinicians may want to consider this for women at highest risk.

Terry MB, Gammon MD, Zhang FF, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004;291:2433-2440.

Related Videos
Understanding combined oral contraceptives and breast cancer risk | Image Credit:
Why doxycycline PEP lacks clinical data for STI prevention in women
The importance of nipocalimab’s FTD against FNAIT | Image Credit:
Enhancing cervical cancer management with dual stain | Image Credit:
Fertility treatment challenges for Muslim women during fasting holidays | Image Credit:
Understanding the impact of STIs on young adults | Image Credit:
CDC estimates of maternal mortality found overestimated | Image Credit:
Study unveils maternal mortality tracking trends | Image Credit:
How Harmonia Healthcare is revolutionizing hyperemesis gravidarum care | Image Credit:
Unveiling gender disparities in medicine | Image Credit:
© 2024 MJH Life Sciences

All rights reserved.